Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
Heliyon ; 10(5): e27216, 2024 Mar 15.
Artículo en Inglés | MEDLINE | ID: mdl-38449660

RESUMEN

Background: Despite the potential of immune checkpoint blockade (ICB) as a promising treatment for Pancreatic adenocarcinoma (PAAD), there is still a need to identify specific subgroups of PAAD patients who may benefit more from ICB. T cell-mediated tumor killing (TTK) is the primary concept behind ICB. We explored subtypes according to genes correlated with the sensitivity to TKK and unraveled their underlying associations for PAAD immunotherapies. Methods: Genes that control the responsiveness of T cell-induced tumor destruction (GSTTK) were examined in PAAD, focusing on their varying expression levels and association with survival results. Moreover, samples with PAAD were separated into two subsets using unsupervised clustering based on GSTTK. Variability was evident in the tumor immune microenvironment, genetic mutation, and response to immunotherapy among different groups. In the end, we developed TRGscore, an innovative scoring system, and investigated its clinical and predictive significance in determining sensitivity to immunotherapy. Results: Patients with PAAD were categorized into 2 clusters based on the expression of 52 GSTTKs, which showed varying levels and prognostic relevance, revealing unique TTK patterns. Survival outcome, immune cell infiltration, immunotherapy responses, and functional enrichment are also distinguished among the two clusters. Moreover, we found the CATSPER1 gene promotes the progression of PAAD through experiments. In addition, the TRGscore effectively predicted the responses to chemotherapeutics or immunotherapy in patients with PAAD and overall survival. Conclusions: TTK exerted a vital influence on the tumor immune environment in PAAD. A greater understanding of TIME characteristics was gained through the evaluation of the variations in TTK modes across different tumor types. It highlights variations in the performance of T cells in PAAD and provides direction for improved treatment approaches.

2.
Front Oncol ; 12: 1002781, 2022.
Artículo en Inglés | MEDLINE | ID: mdl-36158697

RESUMEN

Liver carcinogenesis is a multiprocess that involves complicated interactions between genetics, epigenetics, and transcriptomic alterations. Aberrant chromatin regulator (CR) expressions, which are vital regulatory epigenetics, have been found to be associated with multiple biological processes. Nevertheless, the impression of CRs on tumor microenvironment remodeling and hepatocellular carcinoma (HCC) prognosis remains obscure. Thus, this study aimed to systematically analyze CR-related patterns and their correlation with genomic features, metabolism, cuproptosis activity, and clinicopathological features of patients with HCC in The Cancer Genome Atlas, International Cancer Genome Consortium-LIRI-JP cohort, and GSE14520 that utilized unsupervised consensus clustering. Three CR-related patterns were recognized, and the CRs phenotype-related gene signature (CRsscore) was developed using the least absolute shrinkage and selection operator-Cox regression and multivariate Cox algorithms to represent the individual CR-related pattern. Additionally, the CRsscore was an independent prognostic index that served as a fine predictor for energy metabolism and cuproptosis activity in HCC. Accordingly, describing a wide landscape of CR characteristics may assist us to illustrate the sealed association between epigenetics, energy metabolism, and cuproptosis activity. This study may discern new tumor therapeutic targets and exploit personalized therapy for patients.

3.
Carbohydr Polym ; 268: 118257, 2021 Sep 15.
Artículo en Inglés | MEDLINE | ID: mdl-34127228

RESUMEN

Multifunctional theranostic nanoplatforms integrated of imaging function, multi-modality therapy, stimuli-responsiveness, and targeted delivery are of highly desirable attributes in achieving precise medicine. However, preparation of multifunctional nanoplatforms often involves laborious, multiple steps and inevitably utilizes low-biocompatible or non-functional components. Herein we report a facile, one-step self-assembly strategy to fabricate hyaluronic acid (HA)-based multifunctional tumor theranostic nanoplatform by employing magnetic resonance imaging (MRI) agent Mn2+ as a reversible crosslink agent for histidine-grafted HA, along with simultaneously loading chemotherapeutic agent doxorubicin hydrochloride (DOX) and photodynamic therapy agent chlorin e6, to realize MRI-guided targeted chemo-photodynamic cancer therapy. The targeted delivery and stimuli-responsive payload release were demonstrated in vitro and in vivo. Furthermore, the combined chemo-photodynamic therapy of the nanoassembly dramatically improved the cancer therapeutic outcome, in comparison with that of free DOX and nanoplatform solely loaded DOX in a melanoma bearing mice. Our one step assemble strategy is of great potential in clinic transformation.


Asunto(s)
Antineoplásicos/uso terapéutico , Portadores de Fármacos/química , Nanogeles/química , Neoplasias/diagnóstico por imagen , Neoplasias/tratamiento farmacológico , Fármacos Fotosensibilizantes/uso terapéutico , Animales , Línea Celular Tumoral , Clorofilidas , Doxorrubicina/uso terapéutico , Portadores de Fármacos/toxicidad , Histidina/química , Histidina/toxicidad , Ácido Hialurónico/análogos & derivados , Ácido Hialurónico/toxicidad , Luz , Manganeso/química , Manganeso/toxicidad , Ratones Endogámicos C57BL , Nanogeles/toxicidad , Fotoquimioterapia , Fármacos Fotosensibilizantes/efectos de la radiación , Porfirinas/efectos de la radiación , Porfirinas/uso terapéutico , Medicina de Precisión/métodos , Oxígeno Singlete/metabolismo
4.
Biomater Sci ; 9(10): 3804-3813, 2021 May 18.
Artículo en Inglés | MEDLINE | ID: mdl-33881050

RESUMEN

Nano-graphene oxide (NGO) has attracted increasing attention as an advanced drug delivery system. However, the current surface functionalization and drug-loading of NGO either rely on π-π stacking that is limited to aromatic molecules, or covalent conjugation that requires tedious synthesis. Herein, we developed the first cucurbit[7]uril (CB[7])-conjugated NGO (NGO-CB[7]) that allows non-covalent, modular surface functionalization and drug loading via not only traditional π-π stacking interactions between the NGO surface and functional molecules, but also strong host-guest interactions between CB[7] and guest payloads or adamantane (ADA)-tagged functional molecules, for more versatile biomedical applications. To this end, chlorin e6 (Ce6, a photosensitizer), banoxantrone dihydrochloride (AQ4N, a hypoxia-responsive prodrug) and oxaliplatin (OX, a guest of CB[7]) were co-loaded onto NGO-CB[7] via π-π stacking and host-guest interactions, respectively. Subsequently, ADA-tagged hyaluronic acid (ADA-HA) wrapped NGO-CB[7] non-covalently via CB[7]-ADA host-guest interactions to improve the physiological stability and overall biocompatibility of this supramolecular nanosystem, and to enable targeted delivery into cancer cells with CD44 receptors overexpressed. Remarkably, this supramolecular nanomedicine exhibited significant antitumor efficacy via combined photothermal/photodynamic therapy (PTT/PDT) from NGO/Ce6, as well as dual chemotherapy from OX and AQ4N (activated by PDT-enhanced hypoxia), in vitro and in vivo. This study not only offers a new supramolecular inorganic/organic hybrid nanosystem for multi-modality cancer therapy, but may also provide important new insights into noncovalent functionalization of other carbon nanomaterials and inorganic nanomaterials leading to multifunctional drug delivery systems.


Asunto(s)
Nanomedicina , Neoplasias , Hidrocarburos Aromáticos con Puentes , Imidazoles , Neoplasias/tratamiento farmacológico , Óxidos
5.
ACS Appl Mater Interfaces ; 11(32): 28665-28670, 2019 Aug 14.
Artículo en Inglés | MEDLINE | ID: mdl-31381300

RESUMEN

Polysaccharide-based nanogels have drawn considerable interest in pharmaceutics because of their superior biocompatibility and potential responsiveness to external stimuli, enabling specific drug release. During the fabrication of nanogels, however, covalent cross-linking often involves less friendly cross-linkers and traditionally employed noncovalent cross-linking often relies on weak interactions that may lead to premature payload release. Herein, we report host-guest chemistry-driven supramolecular chitosan nanogels (CNGs) that are responsive to either endogenous or exogenous stimuli, thus allowing selective drug release in specific cancer cells or disease sites. In an aqueous solution, two phenylalanine (Phe) units of Phe-grafted chitosan (CS-Phe) were encapsulated into one cavity of cucurbit[8]uril (CB[8]), driving cross-linking of CS-Phe and formation of CNGs. Doxorubicin hydrochloride (DOX), a chemotherapeutic agent, was entrapped in the matrix of CNGs during the formation of nanogels to yield DOX-CNGs with an excellent drug loading efficiency. The morphology and size of CNGs were fully assessed by transmission electron microscopy and dynamic light scattering. The encapsulated DOX was selectively liberated in the presence of competitive guests of CB[8], such as endogenous spermine (SPM) that is overexpressed by certain types of cancer cells or exogenous amantadine (ADA) that may be added into cells or tissues that require targeted treatment, either of which may replace Phe from the cavity of CB[8] resulting in the breakdown of the nanogels and payload release. The CNGs were efficiently internalized by cells, and the DOX-CNGs exhibited specific, potent activity against cancerous cells such as A549 cell line that is well known for SPM overexpression. This study reports that the first stimuli (competitive guest)-responsive host-guest interactions initiated supramolecular CNGs with excellent biocompatibility and selective therapeutic efficacy against cancer cells. It may provide new insights into the design and fabrication of novel stimuli-responsive payload delivery systems.


Asunto(s)
Quitosano , Doxorrubicina , Sistemas de Liberación de Medicamentos , Nanoestructuras , Neoplasias , Células A549 , Quitosano/química , Quitosano/farmacocinética , Quitosano/farmacología , Doxorrubicina/química , Doxorrubicina/farmacocinética , Doxorrubicina/farmacología , Geles , Humanos , Nanoestructuras/química , Nanoestructuras/uso terapéutico , Neoplasias/tratamiento farmacológico , Neoplasias/metabolismo , Neoplasias/patología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA